| JYSB2400254 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2024-12-09 | | Genentech Inc;Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | | | view |
| CXSS2400134 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products(3.3) | New Drug Application | 2024-12-04 | | Shanghai Henlius Biologics Co Ltd | | | view |
| CXSS2400116 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products(3.3) | New Drug Application | 2024-10-28 | | Hisun Biopharmaceutical Co Ltd | | | view |
| JYSB2300197 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2023-11-14 | | Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | | | view |
| CXSS2300038 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products(3.3) | New Drug Application | 2023-05-24 | | Nanjing Shunxin Pharmaceuticals Co LTDof Chiatai Tianqing Pharmaceutical Group | | | view |
| JYSZ2300019 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | License Renew | 2023-04-21 | | Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG;Roche (China) Holding Ltd | | | view |
| JYSB2300063 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2023-04-11 | | Genentech Inc;Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | | | view |
| JYSB2300016 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2023-02-07 | | Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | | | view |
| JYSB2300009 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2023-01-17 | | Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | | | view |
| CXSS2300002 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products(3.3) | New Drug Application | 2023-01-10 | | QILU Pharmaceutical Co Ltd | | | view |
| JYSB2200111 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2022-06-30 | | Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | | | view |
| CXSL2101162 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products(3.3) | New Drug Application | 2021-06-29 | | CSPC Megalith Biopharmaceutical Co Ltd | | | view |
| JYSB2101061 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2021-06-25 | | Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | | | view |
| JYSB2101013 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2021-04-23 | | Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | | | view |
| JYSB2000696 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2021-01-05 | 罗氏（中国）投资有限公司 | Roche (China) Holding Ltd;Roche Diagnostics GmbH;Roche Pharma (Schweiz) Ltd | Certificate Issued | 2021-03-17 | view |
| JYSB2000662 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2020-12-28 | 罗氏（中国）投资有限公司 | Roche (China) Holding Ltd;Roche Diagnostics GmbH;Roche Pharma (Schweiz) Ltd | In Review | 2020-12-24 | view |
| JYSB2000601 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2020-12-07 | 罗氏（中国）投资有限公司 | Roche (China) Holding Ltd;Roche Diagnostics GmbH;Roche Pharma (Schweiz) Ltd | Filed | 2020-12-17 | view |
| JYSB2000387 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2020-08-21 | 罗氏（中国）投资有限公司 | Roche (China) Holding Ltd;Roche Diagnostics GmbH;Roche Pharma (Schweiz) Ltd | Certificate Issued | 2020-10-15 | view |
| JYSB2000386 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2020-08-21 | 罗氏（中国）投资有限公司 | Roche (China) Holding Ltd;Roche Diagnostics GmbH;Roche Pharma (Schweiz) Ltd | Filed | 2020-09-02 | view |
| JYSB2000140 | 帕妥珠单抗注射液 | pertuzumab | Injection | Biological Products | Supplementary Application | 2020-05-06 | 罗氏（中国）投资有限公司 | Roche (China) Holding Ltd;Roche Diagnostics GmbH;Roche Pharma (Schweiz) AG | In Review | 2020-05-01 | view |
